Vertex Pharmaceuticals

Early-Market Movers: Human Genome Sciences, Ford

By Michael Goldstein| FOXBusiness| Markets

… of 4 cents per share on revenue of $27.26 million. Kopin shares were up 12.6% in pre-market trading. Vertex Pharmaceuticals (VRTX) The company announced a trial of its Telaprevir hepatitis C treatment showed that twice-daily use …

Story|11/02/2009

Market Winners and Losers in 2008

By Kathryn Buschman Vasel| FOXBusiness| Markets

… worst performers for 2008. NASDAQ 100 Gainers Vertex Pharmaceuticals (VRTX) The harmaceutical company closed at $30.38 ..... worst performers for 2008. NASDAQ 100 Gainers Vertex Pharmaceuticals (VRTX) The Pharmaceutical closed at $30 …

Story|12/31/2008